NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT06840119 2026-01-28
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Immunocore Ltd
Phase 1/2 Recruiting
NCT06274437 2024-08-07
A Study of BND-35 in Participants With Advanced Solid Tumors
Biond Biologics
Phase 1 Recruiting
NCT04120246 2024-07-10
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Phase 1 Suspended
NCT01335009 2021-09-01
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai Inc.
Phase 2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02546284 2020-02-28
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Humanigen, Inc.
Phase 1 Completed
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00356460 2014-03-19
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Sanofi
Phase 1 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed
NCT00060138 2013-05-15
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Chugai Pharmaceutical
Phase 1/2 Completed
NCT00094653 2011-07-11
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended